Judith Love, country president Sweden and oncology general manager for the Nordics region for Novartis, underlines the need for a new reimbursement system for cell and gene therapies in the region and explains how the Nordics and Sweden can be a pioneer in this field, by initiating early dialogue between the industry and all stakeholders.
[The Nordics and Sweden] is an open, collaborative ecosystem paired with a very innovative mindset
As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year…
In a fast-changing Nordic CRO industry, CTC Clinical Trial Consultants has opted to differentiate with a unique one-stop-shop approach. CEO Anders Millerhovf reveals how the relatively young company has managed…
With almost three decades of experience in the Swedish life science industry, Jan Hellqvist, general manager of KLIFO in Sweden, explains why the country has seen the number of clinical…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…
See our Cookie Privacy Policy Here